Semax

ResearchChemHQ

$34.99

1 vial · vial

Primary Mechanism: Multi-Pathway Neurotrophic Activation

Semax produces its effects through coordinated activation of multiple neurotrophic, neurotransmitter, and neuroprotective pathways. Unlike conventional nootropics that target a single system (modafinil on orexin, racetams on acetylcholine, stimulants on catecholamine reuptake), Semax appears to upregulate a broad program of neuroprotection and neurogenesis that affects the brain through several parallel mechanisms.

BDNF and NGF Elevation

The most well-characterized mechanism is elevation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). These neurotrophins are critical for:

• Synaptic plasticity and learning
• Adult neurogenesis in the hippocampus
• Protection of neurons from ischemic, excitotoxic, and oxidative damage
• Growth and maintenance of axonal connections
• Mood regulation (low BDNF is associated with depression)

Semax administration increases BDNF expression rapidly (within hours) in multiple brain regions including hippocampus, cortex, and limbic structures (Dolotov et al., 2006). This neurotrophic cascade underlies both acute cognitive effects and chronic mood/cognition improvements.

Dopaminergic Modulation

Semax enhances dopaminergic signaling in prefrontal and striatal circuits relevant to:

• Attention and focus (working memory)
• Motivation and reward processing
• Executive function
• Motor coordination

This dopaminergic effect is thought to contribute substantially to the "cleaner stimulant" experience users describe — alertness and drive without the edge of direct stimulants (Shadrina et al., 2001).

Serotonergic and Melanocortin Pathways

Semax inherits some melanocortin receptor activity from its ACTH parent, particularly at melanocortin MC3 and MC4 receptors. These receptors modulate:

• Mood and stress response
• Sexual function
• Energy balance (modest effects)
• Inflammation

The compound also affects serotonin metabolism, contributing to mood and anxiolytic effects.

Endogenous Opioid Potentiation

Similar to Selank, Semax potentiates activity of endogenous enkephalins through inhibition of enkephalinases (the enzymes that degrade enkephalins). This enhances natural opioid signaling, contributing to:

• Stress tolerance
• Mood elevation
• Analgesic effects in some contexts
• Resilience to psychological stressors

Unlike exogenous opioids, this potentiation does NOT produce dependence, tolerance, or respiratory depression.

Neuroprotection

Semax shows substantial neuroprotective activity:

• Anti-ischemic: Reduces infarct size in stroke models
• Anti-excitotoxic: Protects neurons from glutamate toxicity
• Anti-apoptotic: Inhibits programmed cell death in stressed neurons
• Anti-inflammatory: Modulates neuroinflammation in injury contexts
• Oxidative stress reduction: Activates antioxidant gene expression

These effects are the basis for Semax's clinical use in acute ischemic stroke and are supported by extensive preclinical and clinical evidence (Gusev et al., 2005, Romanova et al., 2012).

Gene Expression Effects

Semax produces broad changes in brain gene expression that may underlie chronic effects:

• Upregulation of neuroprotective and neurotrophic genes
• Modulation of immediate early genes (c-fos, c-jun)
• Epigenetic effects including DNA methylation changes
• Enhanced expression of cytoskeletal and synaptic genes

This gene-expression program helps explain why Semax effects persist beyond the peptide's plasma half-life and why chronic use produces accumulating benefits.

Absence of ACTH Activity

Critically, despite being derived from ACTH(4-10), Semax does NOT stimulate adrenal cortisol production. The structural modifications remove the HPA-axis activating capability while preserving the CNS effects. This means:

• No elevation of serum cortisol
• No adrenal stimulation
• No stress hormone response
• Selective brain-targeted action

This selectivity is a key pharmacological advantage — the cognitive and neurotrophic effects of the ACTH fragment are retained without the hormonal burden.

Pharmacokinetics

Standard intranasal delivery:

• Onset of effects: 15-30 minutes post-administration
• Peak effects: 30-60 minutes
• Duration of action: 4-8 hours per dose, though chronic effects extend
• Plasma half-life: Very short — intact peptide cleared from plasma within 1-2 hours
• Bioavailability via intranasal route: Much higher than oral (which is essentially zero due to GI degradation); intranasal provides direct nose-to-brain delivery via olfactory pathway
• CNS targeting: Direct delivery to brain parenchyma via olfactory and trigeminal pathways, bypassing blood-brain barrier
• Metabolism: Enzymatic cleavage to smaller peptide fragments; some fragments may retain activity

Intranasal Advantage

The intranasal route is crucial for Semax's therapeutic utility. Oral administration would result in complete GI degradation of the peptide. Subcutaneous injection produces primarily peripheral exposure with limited CNS targeting. Intranasal delivery provides direct nose-to-brain access through:

1. Olfactory pathway — peptides cross the cribriform plate and enter the brain directly
2. Trigeminal pathway — additional direct neural access
3. Limited systemic absorption — minimizes peripheral exposure while maximizing CNS effect

This is why Semax is almost exclusively used intranasally in both approved Russian formulations and off-label research chemical use.

Dose Concentrations

Two standard Russian formulations:

• 0.1% intranasal solution (1 mg/mL = 1,000 mcg/mL): For nootropic and cognitive enhancement indications. Each 50 mcL spray delivers 50 mcg; 2 sprays each nostril delivers 200 mcg.
• 1% intranasal solution (10 mg/mL = 10,000 mcg/mL): For neurological indications (stroke, optic nerve). Each 50 mcL spray delivers 500 mcg; 2 sprays each nostril delivers 2,000 mcg (2 mg).

Research chemical suppliers typically offer 0.1% formulations matching the lower-concentration nootropic product. Higher concentrations exist but are less commonly used in biohacking.

Chronic Dosing Effects

Regular Semax administration produces accumulating effects through:

• Sustained BDNF elevation
• Neurotrophic gene expression changes
• Possible neurogenesis
• Long-term synaptic adaptations

This chronic effect profile means that acute single-dose trials may underestimate Semax's clinical value. Benefits often accumulate over 2-6 weeks of regular use, similar to SSRIs but without the activation period.

Selective Dopaminergic Effects

A distinguishing feature of Semax compared to conventional stimulants is the quality of dopaminergic effect. Semax:

• Produces moderate, sustained dopaminergic enhancement
• Does NOT cause the sharp dopamine spike of amphetamine or methylphenidate
• Does NOT produce tolerance or requirements for escalating doses
• Does NOT cause the dopamine crash after stimulant use
• Does NOT produce abuse/addiction patterns

This profile explains why Semax is useful for sustained cognitive output without the "amphetamine tax" — the post-stimulant fatigue, sleep disruption, and mood effects.

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro, MEHFPGP, 813 Da molecular weight) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s. The compound is derived from ACTH(4-10) — the 4-10 amino acid fragment of adrenocorticotropic hormone — with the addition of a Pro-Gly-Pro C-terminal tail that confers resistance to enzymatic degradation while preserving neurotropic activity. Critically, Semax retains the cognitive, neurotrophic, and neuroprotective effects of its ACTH parent while completely lacking the adrenal-stimulating hormonal activity. In other words, Semax works on the brain without activating the HPA axis or affecting cortisol production — a therapeutically ideal profile.

Semax was patented in 1982 by Russian researchers and achieved regulatory approval in the Russian Federation in 2000, where it is prescribed at pharmacies for cerebrovascular disorders (ischemic stroke recovery), optic nerve disorders, minimal brain dysfunction in children (ADHD-like presentations), asthenia, and various cognitive complaints. It is available in two commercial strengths: 0.1% intranasal solution for cognitive-nootropic indications and 1% intranasal solution for stroke recovery and neurological deficits. In Western markets, Semax has never been submitted for FDA, EMA, or other major regulatory approval — a pattern common to Russian neuropeptides that lack patent protection and Western pharmaceutical sponsors. It circulates in US and European biohacking communities through research chemical peptide suppliers and is considered one of the most potent, best-tolerated nootropic compounds available.

The pharmacology of Semax is genuinely notable and spans multiple neurological domains. At the molecular level, Semax elevates BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) expression in the brain, promotes dopaminergic and serotonergic signaling, potentiates endogenous enkephalin activity, and upregulates expression of neuroprotective genes. At the clinical level, it produces cognitive enhancement (attention, memory, executive function), mood elevation, stress tolerance, neuroprotection during ischemia, and accelerated recovery from neurological injury. Russian clinical trials in acute ischemic stroke — the best-documented Semax indication — show meaningful improvements in functional recovery when Semax is administered within 6-24 hours of stroke onset, likely through direct neuroprotection plus enhanced neurogenesis during recovery. The stroke literature is the only domain where Semax has truly rigorous clinical trial evidence (Gusev et al., 2005).

In the biohacking and cognitive enhancement community, Semax has achieved a reputation as the "premier Russian nootropic" — often positioned alongside Selank, Noopept, Modafinil, and racetams in the advanced cognitive stack. Users typically report improvements in focus, working memory, verbal fluency, motivation, stress tolerance, and overall cognitive throughput. The effects are often described as "clean" — producing alertness and engagement without the jitters of stimulants, without the emotional blunting of SSRIs, and without the sedation of anxiolytics. Dose-response is relatively modest (300-900 mcg daily typical), onset is rapid (15-30 minutes after intranasal administration), and effects last several hours per dose. Chronic use over weeks produces accumulating cognitive and mood benefits that appear to outlast plasma presence.

This entry covers Semax pharmacology, the genuinely rigorous Russian stroke evidence base, the more speculative cognitive enhancement applications, protocol considerations, and safety profile. It should be read as an educational reference — Semax is not FDA-approved, is distributed through gray-market channels with variable quality, and anyone considering use should obtain reliable product, start conservatively, and have realistic expectations. Cross-reference with Selank, DSIP, and Epithalon for Russian peptide context, and with Noopept, Piracetam, and Modafinil for broader nootropic comparisons.

IUPAC Name

Met-Glu-His-Phe-Pro-Gly-Pro

CAS Number

80714-61-0

Molecular Formula

C39H56N10O10S

Molecular Mass

813.93 g/mol

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Interaction Matrix

Get Semax Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it. Current lowest: $32.90

Sign in to set alerts

Related Compounds

View All

Side-by-Side Comparisons

All Comparisons

Related Articles

All Posts

ResearchChemHQ

$34.99

Data Completeness

100%

COA Verification

High verification rate (83%)

Research Credibility